title: Therapeutic strategies for the treatment of multiple myeloma.
abstract: The outcome of patients with myeloma has improved significantly in the past decade with the incorporation of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor, bortezomib. Considering nearly all patients relapse, myeloma remains an active area of investigation. There are several promising classes of agents including next generation immunomodulatory agents, proteasome inhibitors, antibody and antitumor immunotherapy approaches that are being evaluated. This article provides an overview on the therapeutic strategies in the treatment of multiple myeloma.
authors: Department of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, Massachusetts 02114, USA.
authors: Neeraj
authors: N
authors: Saini
authors: Anuj
authors: A
authors: Mahindra
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D016207:Cytokines / Q000378:metabolism; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006706:Homeostasis; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000379:methods; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000628:therapy*; D009842:Oligopeptides / Q000627:therapeutic use; D011379:Prognosis; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence; D053668:Syndecan-1 / Q000378:metabolism; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D016207:Cytokines; D009842:Oligopeptides; D011480:Protease Inhibitors; D011719:Pyrazines; C508241:SDC1 protein, human; D053668:Syndecan-1; D013792:Thalidomide; D000069286:Bortezomib; C524865:carfilzomib; C467566:pomalidomide; D051997:ADP-ribosyl Cyclase 1; D000077269:Lenalidomide